Leaders of the Global Liquid Biopsy Revolution
As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD).
Plasma-Safe-SeQs NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.
-
Branche
-
Biotechnologieforschung
-
Größe
-
51–200 Beschäftigte
-
Hauptsitz
-
Baltimore, Maryland
-
Art
-
Kapitalgesellschaft (AG, GmbH, UG etc.)
-
Gegründet
-
2008
-
Spezialgebiete
-
Mutation Detection, Sequence Analysis, Oncology, Molecular Diagnostics, circulating tumor dna, ctDNA, Plasma NGS, Next Generation Sequencing , digital PCR , BEAMing, Clinical Trials , NGS, CLIA, GCP, Cancer, Molecular Testing, Medicine, Research, IVD Kit , Plasma-Safe-SeqS, Liquid Biopsy, cfDNA, cell free DNA, cfHPV-DNA und LBx
